



The IAS-USA Annual Update on HIV Management in Chicago, Illinois (Offered In-Person and Virtually)

Chicago, Illinois | October 15, 2026



IAS-USA
International Antiviral Society-USA

Contents

International Antiviral Society–USA	3
Course Co-Chairs and Faculty	6
Course Faculty and Organizers’ Financial Relationships With Ineligible Companies	7
Continuing Education Credits	8
Accreditation Statement and CME Credits	8
ABIM MOC Points for Internal Medicine Specialists and Subspecialists	8
Nursing Continuing Education Contact Hours	8
Pharmacy Continuing Education Contact Hours	8
Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation	9

Mission

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scientific Leadership Board

The volunteers of the Scientific Leadership Board guide the needs assessment, design, development, and evaluation of the educational and scientific programming of the in-person and virtual courses, webinars and *Topics in Antiviral Medicine*[™]. Visit www.iasusa.org/about/ias-usa-scientific-leadership-board/ for a list of Scientific Leadership Board members.

IAS–USA Governance

The IAS–USA Governance members provide administrative oversight for the operations and mission of the IAS–USA. Non-Staff Members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. Visit <https://www.iasusa.org/about/ias-usa-governance/> for a list of IAS–USA Governance members.

Improving the Management of HIV Disease®: Advanced CME Courses IN HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

The 1-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. The virtual courses are half-day updates that focus on the key issues clinicians are likely facing.

Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely,

scientifically rigorous, and clinically relevant information about HIV disease management. Visit www.iasusa.org/activities/live-courses/hiv-courses/ for more information on upcoming and on-demand CME courses.

Webinars

The IAS–USA offers state-of-the-art webinars on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. They are led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and provides continuing education credits. Visit www.iasusa.org/activities/webinars/upcoming-webinars/ for upcoming webinars. On-demand webinars offer CME credit for a year at www.iasusa.org/activities/webinars/on-demand-webinars/.

Webinar topics and presenters are identified by the *Content on the Web* (COW) Board, a select group of experts in the management of HIV and other viral infections. Visit www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ for a list of COW Board members.

***Topics in Antiviral Medicine*[™]**

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine*[™] (TAM) 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of people with HIV or other viral infections. The journal offers CME credit and is indexed on Index Medicus/MEDLINE. Visit to <https://www.iasusa.org/activities/topics-in-antiviral-medicine/current-issues/> view the recent TAM issues.

Conference on Retroviruses and Opportunistic Infections

The IAS–USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014 to 2026 are available at www.CROIconference.org.

CROI 2027 will be held in San Diego, California from March 21 to 24, 2027.

Ryan White HIV/AIDS Program CLINICAL CONFERENCE

The Ryan White HIV/AIDS Program (RWHAP) **CLINICAL CONFERENCE** is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society–USA (IAS–USA). This conference is coordinated through the AIDS Education and Training Centers (AETC) clinician training network.

The RWHAP **CLINICAL CONFERENCE** 2026 will be held in Seattle, WA, from December 13-15, 2026.

Conference on Bacteriophages: Biology, Dynamics, and Therapeutics

Over the past 2 decades, antimicrobial resistant (AMR) bacterial infections have emerged as one of the most important contributors to global morbidity and mortality. Despite major investments in the discovery of new generations of traditional small molecule antibiotics, the pace of traditional antibiotic discovery has fallen behind that of the evolution of AMR pathogens. Bacteriophages have recently re-emerged as an effective adjunct to small molecule antibiotics for the treatment of AMR bacterial infections. Although a century of experience in Eastern European countries has provided anecdotal support for bacteriophage therapy, the efficacy of bacteriophage therapeutics has yet to be established through traditional translational and clinical investigation. As Bernard Fields articulated at an analogous period in HIV therapeutic research, “it is time to return to the basics.” In response, the Conference on Retroviruses and Opportunistic Infections (CROI) was introduced as a critical catalyst, bringing together the full breadth of the scientific community to develop a research agenda that led to major reductions in HIV-related morbidity and mortality.

There is no similar academic conference hosted in North America that combines exploration of biology, physiologic dynamics, and the therapeutic potential of bacteriophages. This conference fulfills this need, bringing together fundamental studies on all aspects of phage biology with critical exploration of their clinical

applications. The conference is planned to meet biennially, in odd-numbered years.

The inaugural conference was held in Washington, DC, from October 12 to 14, 2025.

Treatment and Testing Guidelines

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA volunteer Antiretroviral Guidelines Panel, were last published in the *Journal of the American Medical Association* on December 1, 2024 (Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society–USA panel. *JAMA*. 2024:E1-E21). *JAMA* offers free access to the paper at <https://jamanetwork.com/journals/jama/fullarticle/2827545>. The 2024 iteration includes updated recommendations on the use of antiretroviral medications for the treatment and prevention of HIV in developed-world settings. Initial therapy, approaches for switching therapy, and effective strategies for managing coinfections are discussed. There are new tools for preventing cardiovascular disease in people with HIV and for reducing the incidence of selected sexually transmitted infections. HIV prevention through preexposure prophylaxis remains a dynamic field, with several recent breakthroughs. Improving the care of people with HIV who have substance use disorder and addressing HIV care disparities remain challenges and high priorities.

HIV Drug Resistance Mutations

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. A volunteer panel of acknowledged leaders in the field

collect and review the information on relevant mutations. This information, last updated in March 2025, is available on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

IAS–USA Dialogues Series: Emerging Infections and Health Threats

IAS–USA Dialogues (formerly COVID-19 Dialogues) were created to address an urgent need for reliable scientific information, with understanding of SARS-CoV-2 and COVID-19 disease changing almost daily. In response, the IAS–USA created a program that brought together leading experts to discuss the latest data and research regarding COVID-19. Although the Dialogues continue to cover the latest in COVID-19 developments, IAS–USA Dialogues have also expanded to include the latest emerging and reemerging urgent viral outbreaks, including mpox, polio, and flu. The Dialogue series is intended for healthcare clinicians and researchers, including infectious disease and HIV specialists.

Visit www.iasusa.org/activities/covid-19-dialogue-series/ for upcoming live Dialogues. The conversations are available on-demand as webcasts and podcasts after they are broadcast at www.iasusa.org/activities/covid-19-dialogue-series/on-demand/.

IAS–USA Going anti-Viral Podcast

Going *anti-Viral* is a clinical information podcast for clinicians, produced by the IAS–USA. This podcast is intended as a technical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections.



Now available on
Apple Podcasts and Spotify

Going *anti-Viral*'s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalog of panel discussions, Dialogues, and other audio from various meetings and conferences.

Podcasts

Many past IAS–USA activities are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations.

Practice Question of the Week

This initiative started in 2021 and highlights updates to relevant practice guidelines or identified practice gaps. Each question is programmed as a pop-up and on the [Practice Question of the Week](#) page on the IAS–USA website. Participants receive immediate feedback with the correct answer, explanation, and links to more resources. Visit www.iasusa.org/practice-question-of-the-week/ to view the most recent question and to see past questions.

Presentation Slides

The IAS–USA offers a collection of downloadable slides from presentations at conferences or past IAS–USA live courses. Presenters have selected the slides they consider the most informative and relevant. Slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.



For information about any of these programs, please visit www.IASUSA.org.

Email: info@iasusa.org Phone: (415) 544-9400

Course Co-Chairs and Faculty

Co-Chairs



Constance A. Benson, MD
Professor of Medicine
Division of Infectious Diseases and
Global Public Health
UCSD Antiviral Research Center (AVRC)
UCSD Center for Innovative Phage Applications
& Therapeutics (IPATH)
Co-Investigator, UCSD HIV Collaborative
Clinical Trials Unit
University of California San Diego
San Diego, CA



Aniruddha Hazra, MD
Associate Professor of Medicine
Section of Infectious Diseases and
Global Health
Director, Infectious Diseases
Fellowship Program
Medical Director, UCM Sexual
Wellness Clinic
Director of STI Services, Chicago
Center of HIV Elimination
University of Chicago
Chicago, IL

Speakers and Panelists



Todd T. Brown, MD, PhD
Professor of Medicine and Epidemiology
Division of Endocrinology, Diabetes,
and Metabolism
Deputy Director, Institute for Clinical
and Translational Research
Director, ICTR Clinical Research Units
Johns Hopkins University
Baltimore, MD



Shelli Farhadian, MD, PhD
Associate Professor of Medicine
Division of Infectious Diseases
Yale School of Medicine
New Haven, CT



David Burger, PharmD, PhD
Professor of Clinical Pharmacy
Department of Pharmacy, Pharmacology
and Toxicology
Radboud University Medical Center
Nijmegen, The Netherlands



Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Chief, Division of Infectious Diseases
Associate Dean for Clinical Research
Attending Physician, New York
Presbyterian Hospital
Weill Cornell Medicine
New York, NY



Eric S. Daar, MD
Professor of Medicine
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, CA



Sandra A. Springer, MD
Professor of Medicine
Department of Internal Medicine
Section of Infectious Diseases
Yale School of Medicine
Yale AIDS Program
New Haven, CT

Course Faculty and Organizers' Financial Relationships With Ineligible Companies

Faculty Financial Disclosure

It is the policy of IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All parties with control over the content of IAS–USA activities (eg, conference co-chairs, faculty, and IAS–USA staff) are required to disclose to the organization and activity audience any financial relationships with ineligible companies (formerly described as commercial interests by the ACCME) within the previous 24 months. The ACCME defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

It is IAS–USA policy to separate ineligible company promotion from its core educational and informational activities. Individuals who conduct marketing or promotional activities for ineligible companies may not contribute to IAS–USA programs. A marketing or promotional activity includes any activity in which the ineligible company controls key elements, such as speaker or topic selection that could be used to serve the ineligible company's interests (eg, speakers' bureaus, lectures, and advertorials). Individuals may not participate in most IAS–USA programs for 12 months after functioning in a promotional or marketing effort for an ineligible company.

IAS–USA policy requires that it resolve any real or apparent conflict of interest that may influence the development, content, or delivery of its educational activities prior to the activity being delivered to participants.

The IAS–USA has identified and resolved ahead of time any possible conflicts of interest that may influence this CME activity with regard to exposition or conclusion.

All relevant financial relationships with ineligible companies have been mitigated among the planners and the presenters.

The IAS–USA has several mechanisms for resolving conflicts of interest in educational activities. If the conflict of interest cannot be resolved through these mechanisms, the party is recused from the activity.

It is the policy of IAS–USA to publish the financial relationships with ineligible companies of all parties in control of the content of its activities on activity materials or, in cases where space is limited (eg, reprints of figures), on the IAS–USA website, through a web address printed on the activity material. This information will also be provided directly by the IAS–USA office upon request. Individuals who refuse to disclose financial relationships with ineligible companies will not participate in the CME activity.

The Conference Faculty and Organizers' Financial Relationships With Ineligible Companies are available in the [eSyllabus Book](#) page.

Continuing Education Credits

Accreditation Statement and CME Credits

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in this live activity.



The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of **5.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points For Internal Medicine Specialists and Subspecialists



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **5.5 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Education Contact Hours

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider #5-115. This program is approved for **5.5** hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for **5.5** hours of pharmacotherapy credit.

Pharmacy Continuing Education Contact Hours



Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for **5.5** contact hours (0.55 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-26-073-L02-P

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

Obtaining CME credits, ABIM MOC points, Nursing or Pharmacy credits, or a certificate of participation will require that you complete the online evaluation form and the postactivity assessment for the activity. A link to the evaluation form and the postactivity assessment will be activated in your IAS–USA account under “**My Activities**,” after the course.

Please submit the evaluation and your continuing education claim form (if applicable) by **November 15, 2026**. Your certificate will be available in your account on the IAS–USA website immediately after you submit the evaluation and claim form.

To Begin the Claiming Process

1. Go to <http://www.iasusa.org/> and log in to your IAS–USA account.
2. Hover over your name and click **My Activities**.
3. Find the relevant activity in the table and, in the far-right column, click on the **gray sunburst icon** (☀).
4. Complete the evaluation.

For CME Credits and/or ABIM MOC Points

You need an ABIM ID number to earn ABIM MOC points. This is a 6-digit number issued by ABIM. Be sure to include that number and your date of birth on your IAS–USA profile page.

1. When you get to the end of the evaluation, click **Submit Form**. Click **Take the CME/ABIM MOC posttest** to start the test. Note: **Be sure to indicate if you will be claiming ABIM MOC points, which will require a passing grade of 70%.**
2. **FINAL STEP:** After completing the posttest, at the top of the Thank You page, click **Online CME Claim Form**, where, once logged in, you will: a) answer “Yes” to the question “Are you a licensed physician?” b) enter the CME hours you wish to claim, and c) click Submit.

You need an ABIM ID number to earn ABIM MOC points. This is a 6-digit number issued by ABIM. Be sure to include that number and your date of birth on your IAS–USA profile page.

For Nursing, Pharmacotherapy, Pharmacy Credits, or a Certificate of Participation

1. When you get to the end of the evaluation, click **Submit Form**. Click **Take the CE posttest** to start the test.
2. **FINAL STEP:** After completing the posttest, at the top of the Thank You page, click **Online CME Claim Form**, where, once logged in, you will: a) answer “No” to the question “Are you a licensed physician?” and b) click Submit.

We work with Educational Review Systems to deliver credits to nursing and pharmacy professionals. For nursing credits, your credit notification will be emailed directly from that organization within 30 days after the deadline to claim credits. For pharmacy credits, your credits will be posted to your NABP CPE profile directly from that organization within 30 days after the deadline to claim credits.

Be sure to provide your 6 digit NABP CPE number and your date of birth on your IAS–USA profile. Your claim will not be approved without them.

To Access Your Certificate

Once the claiming process is completed, a certificate will be available for you to print. You can also view your certificate from your IAS–USA account under **My Activities**. Find the relevant activity in the table and, in the far-right column, click on the **green sunburst icon** (☀) to print your certificate.